Anaptysbio (ANAB) EBITDA (2016 - 2026)
Anaptysbio (ANAB) posted EBITDA of -$34.6 million for Q1 2026, down 151.77% on a QoQ basis from $66.9 million in Q4 2025, and down 25.77% year-over-year from -$46.7 million in Q1 2025.
Anaptysbio (ANAB) EBITDA (2016 - 2026) Analysis & Trends
Anaptysbio's EBITDA history runs 11 years deep, the most recent figure standing at -$34.6 million for Q1 2026.
- Quarterly EBITDA fell 25.77% year-over-year to -$34.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.8 million (up 140.68% YoY) and the FY2025 annual result came in at $47.9 million, up 141.67% from the prior year.
- EBITDA was -$34.6 million for Q1 2026 at Anaptysbio, down from $66.9 million in the prior quarter.
- Across five years, EBITDA topped out at $66.9 million in Q4 2025 and bottomed at -$44.4 million in Q1 2023.
- A 5-year average of -$22.4 million and a median of -$29.6 million in 2022 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2022 — EBITDA slumped 5115.57% — and 2025, when it soared 791.84%.
- Anaptysbio's EBITDA stood at -$26.0 million in 2022, then sank by 62.23% to -$42.1 million in 2023, then jumped by 77.05% to -$9.7 million in 2024, then soared by 791.84% to $66.9 million in 2025, then slumped by 151.77% to -$34.6 million in 2026.
- Business Quant data shows ANAB's EBITDA at -$34.6 million in Q1 2026, $66.9 million in Q4 2025, and $34.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | Anaptysbio | 1.55 Bn | 1.27 Bn | - | -34.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.64 Mn |
| Dec 31, 2025 | 66.90 Mn |
| Sep 30, 2025 | 34.70 Mn |
| Jun 30, 2025 | -26.17 Mn |
| Mar 31, 2025 | -27.54 Mn |
| Dec 31, 2024 | -9.67 Mn |
| Sep 30, 2024 | -22.76 Mn |
| Jun 30, 2024 | -40.32 Mn |
| Mar 31, 2024 | -42.20 Mn |
| Dec 31, 2023 | -42.14 Mn |
| Sep 30, 2023 | -37.73 Mn |
| Jun 30, 2023 | -40.14 Mn |
| Mar 31, 2023 | -44.40 Mn |
| Dec 31, 2022 | -25.97 Mn |
| Sep 30, 2022 | -29.63 Mn |
| Jun 30, 2022 | -27.80 Mn |
| Mar 31, 2022 | -31.75 Mn |
| Dec 31, 2021 | -31.16 Mn |
| Sep 30, 2021 | -6.76 Mn |
| Jun 30, 2021 | -533,000.00 |